Skin sensitization testing strategy and in-house fit-for-purpose validations at Charles River Laboratories



C.S. Roper¹, J.L. Vinall¹, J.B. Welch¹, J.J.C. Paulussen², J.C.W. Rijk³ and W.M.A. Westerink³

1 No Vitro Sciences, Charles River, Tranent, United Kingdom. Regulatory Affairs, Charles River Laboratories, 's-Hertogenbosch, The Netherlands. Sciences, Charles River, Tranent, United Kingdom. Regulatory Affairs, Charles River Laboratories, 's-Hertogenbosch, The Netherlands. Sciences, Charles River, Tranent, United Kingdom. Regulatory Affairs, Charles River Laboratories, 's-Hertogenbosch, The Netherlands. Sciences, Charles River, Tranent, United Kingdom. Regulatory Affairs, Charles River Laboratories, 's-Hertogenbosch, The Netherlands. Sciences, Charles River, Tranent, United Kingdom. Regulatory Affairs, Charles River Laboratories, 's-Hertogenbosch, The Netherlands. Regulatory Regulatory Affairs, Charles River, Tranent, United Kingdom. Regulatory Affairs, Charles River Laboratories, 's-Hertogenbosch, The Netherlands. Regulatory Regulatory Affairs, Charles River, The Netherlands. Regulatory Regulatory Affairs, Charles River, Charles River, The Netherlands. Regulatory Regulatory Regulatory Affairs, Charles River, Charles Riv



INTRODUCTION

The implementation of non-animal alternatives for skin sensitization testing has been driven by legislative changes, the 3Rs, and animal welfare considerations. The skin sensitization Adverse Outcome Pathway (AOP) testing comprises tests to address different key events in the AOP: peptide binding, antioxidant response element (ARE) mediated gene expression and dendritic cell activation.

The skin sensitization AOP is now specifically requested for REACH and EU Cosmetic Directive submissions but, due to the complexity of the AOP, no single *in vitro* test is capable of fully classifying substances into UN GHS categories. A number of tests are (or will soon be) accepted by OECD *via* EURL EVCAM. These tests are performed in a tiered testing strategy utilizing *in silico* (*i.e.* Derek), *in chemico* (*i.e.* DPRA, OECD 442C) and *in vitro* assays (including ARE-Nrf2 Luciferase Test, OECD 442D; h-CLAT, OECD 442E and U-SENS™, draft OECD test guideline). These tests are anticipated to almost completely replace *in vivo* tests such as LLNA (OECD 442A). Currently, for potency, REACH will almost certainly require LLNA.

Charles River Laboratories has performed fit-for-purpose validations of DPRA, ARE-Nrf2 Luciferase (KeratinoSens[™], LuSens), h-CLAT and U-SENS[™] tests using appropriate chemical proficiency panels. A testing strategy is also required to allow appropriate collation and interpretation of the results of the multiple tests. A proposed tiered strategy is presented.



METHODS

DPRA was performed according to OECD 442C (2015) OECD Guideline for the Testing of Chemicals: *In Chemico* Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA).

KeratinoSens[™] assay was performed according to OECD 442D (2015) OECD Guideline for the Testing of Chemicals: *In Vitro* Skin Sensitisation: ARE-Nrf2 Luciferase Test Method.


LuSens assay was performed according to Protocol LuSens Assay (BASF, personal communication) and Ramirez *et al.* (2014) LuSens: A keratinocyte based ARE reporter gene assay for use in integrated testing strategies for skin sensitisation hazard identification, Toxicology *in Vitro* 28; 1482–1497.

h-CLAT assay was performed according to OECD 442E (2016) OECD Guideline for the Testing of Chemicals: *In Vitro* Skin Sensitisation: human Cell Line Activation Test (h-CLAT).

U-SENS[™] assay was performed according to draft OECD guideline (2016) OECD Guideline for the Testing of Chemicals: *In Vitro* Skin Sensitisation: U937 Skin Sensitisation Test (U-SENS[™]).



Proposed 2 out of 3 Test Strategy for Mono-constituents (non-UVCB)



DPRA	ARE-Nrf2	Conclusion
Negative	Negative	Non-Sensitizer: Weight of Evidence approach
Positive	Positive	Sensitiser: Potency evaluation required
Positive	Negative	h-CLAT or U-SENS™
Negative	Positive	2 out of 3 approach to determine sensitiser / non-sensitizer
Inconclusive*	Inconclusive*	If sensitiser: further potency evaluation may be required



RESULTS

KeratinoSens[™] Assay Test Panel and Results

Reference Chemical	In Vivo	Experiment 1				Experiment 2				KeratinoSens™	Correct
	Classification	$EC_{1.5}(\mu M)$	I _{max}	IC ₃₀ (μΜ)	IC ₅₀ (μΜ)	EC _{1.5} (μΜ)	I max	IC ₃₀ (μΜ)	IC ₅₀ (μΜ)	Classification	Classification?
2,4-Dinitro-chlorobenzene	Positive (Extreme)	1.64	11.6	6.96	8.34	1.59	14.0	6.04	15.54	Positive	Yes
4-Methylaminophenol sulfate	Positive (strong)	3.22	3.46	11.9	15.3	3.02	8.24	10.06	10.93	Positive	Yes
Methyldibromo glutaronitrile	Positive (strong)	18.8	1.71	26.1	33	4.22	4.93	15.5	17.5	Positive	Yes
2-Mercaptobenzothiazole	Positive (moderate)	1586	3.5	2353	>2400	371	2.43	689	1310	Positive	Yes
Cinnamyl alcohol	Positive (weak)	49.2	12.8	2195	>2310	14.9	6.95	1316	2013	Positive	Yes
Ethylene glycol dimethacrylate	Positive (weak)	38.9	137	579	793	22.7	56.5	548	724	Positive	Yes
Isopropanol	Negative	NA	1.37	NA	NA	NA	1.34	NA	NA	Negative	Yes
Salicylic acid	Negative	NA	1.41	NA	NA	NA	1.22	NA	NA	Negative	Yes
Lactic acid	Negative	NA	1.24	NA	NA	NA	0.97	NA	NA	Negative	Yes
Glycerol	Negative	NA	1.32	NA	NA	NA	1.06	NA	NA	Negative	Yes

LuSens Assay Test Panel and Results

Reference Chemical	In vivo	Luciferase	Induction	LuSens	Correct	
Reference Chemical	Classification	Run 1 ^A	Run 2 ^A	Classification	Classification?	
2,4-Dinitrochlorobenzene	Sensitiser (extreme)	3.08 ± 0.53	2.40 ± 0.12	Positive	Yes	
4-Methylaminophenol sulphate	Sensitiser (strong)	3.25 ± 0.45	3.16 ± 0.80	Positive	Yes	
Methyldibromo glutaronitrile	Sensitiser (strong)	3.08 ± 0.26	2.29 ± 0.73	Positive	Yes	
2-Mercaptobenzothiazole	Sensitiser (moderate)	8.25 ± 0.93	10.94 ± 0.84	Positive	Yes	
Cinnamyl alcohol	Sensitiser (weak)	8.11 ± 2.02	7.84 ± 1.30	Positive	Yes	
Ethyleneglycol dimethylacrylate	Sensitiser (weak)	56.21 ± 1.17	33.93 ± 3.29	Positive	Yes	
Glycerol	Non-sensitiser	0.84 ± 0.11	0.83 ± 0.29	Negative	Yes	
Salicylic acid	Non-sensitiser	0.59 ± 0.07	0.71 ± 0.11	Negative	Yes	
DL-Lactic Acid	Non-sensitiser	1.02 ± 0.22	0.89 ± 0.08	Negative	Yes	
Isopropanol	Non-sensitiser	0.86 ± 0.07	0.51 ± 0.15	Negative	Yes	

U-Sens[™] Assay Results

Octio 7 (33ay 1 (C3a)(3
CRL Data for Prospective Multicentre Study.
Sensitivity 94.7% (18/19)
Specificity 94.7% (18/19)
Accuracy 94.7% (36/38)
pée <i>et al.</i> (2015) oird <i>et al.</i> (2015)

DPRA Assay Test Panel and Results

Reference Chemical	In vivo Classification	F	Reactivity Clas	S	DPRA	Correct
Reference Chemical	III VIVO Glassification	Run 1	Run 2	Run 3	Classification	Classification?
p-Benzoquinone	Sensitiser (extreme)	High	High	High	Sensitiser	Yes
2,4-Dinitrochlorobenzene	Sensitiser (extreme)	High	High	High	Sensitiser	Yes
Oxazolone	Sensitiser (extreme)	High	High	High	Sensitiser	Yes
Formaldehyde	Sensitiser (strong)	Moderate	Moderate	Moderate	Sensitiser	Yes
2-Phenylpropionaldehyde	Sensitiser (moderate)	Moderate	High	High	Sensitiser	Yes
Diethyl Maleate	Sensitiser (moderate)	High	High	High	Sensitiser	Yes
Benzylideneacetone	Sensitiser (moderate)	High	High	High	Sensitiser	Yes
Farnesal	Sensitiser (weak)	Moderate	Moderate	Moderate	Sensitiser	Yes
2,3-Butanedione	Sensitiser (weak)	High	High	High	Sensitiser	Yes
4-Allylanisol	Sensitiser (weak)	Moderate	Moderate	Moderate	Sensitiser	Yes
Hydroxycitronellal	Sensitiser (weak)	Low	Moderate	Low	Sensitiser	Yes
Butanol	Non-sensitiser	Minimal	Minimal	Minimal	Non-sensitiser	Yes
6-Methylcoumarin	Non-sensitiser	Minimal	Minimal	Minimal	Non-sensitiser	Yes
Lactic Acid	Non-sensitiser	Minimal	Minimal	Minimal	Non-sensitiser	Yes
4-Methoxyacetophenone	Non-sensitiser	Minimal	Minimal	Minimal	Non-sensitiser	Yes

h-CLAT Assay Test Panel and Results

TI-OL/TI Moday Tool I dilorand Noodilo									
In vivo	CD54 RFI ^A				CD86 RFI ^A		hCLAT	Correct	
Classification	Run 1	Run 2	Run 3	Run 1	Run 2	Run 3	Classification	Classification?	
Sensitiser (Extreme)	921	281	N/R	194	256	N/R	Positive	Yes	
Sensitiser (Strong)	500	500	N/R	245	177	N/R	Positive	Yes	
Sensitiser (Moderate)	1956	1443	N/R	232	192	N/R	Positive	Yes	
Sensitiser (Moderate)	526	296	N/R	122	338	N/R	Positive	Yes	
Sensitiser (Weak)	129	271	N/R	178	156	N/R	Positive	Yes	
Sensitiser (Weak)	2506	386	N/R	361	130	N/R	Positive	Yes	
Non-Sensitiser	152	36	31	171	97	62	Negative	Yes	
Non-Sensitiser	88	47	N/R	85	85	N/R	Negative	Yes	
Non-Sensitiser	78	192	N/R	192	114	N/R	Negative	Yes	
Non-Sensitiser	139	32	N/R	99	47	N/R	Negative	Yes	
	Classification Sensitiser (Extreme) Sensitiser (Strong) Sensitiser (Moderate) Sensitiser (Moderate) Sensitiser (Weak) Sensitiser (Weak) Non-Sensitiser Non-Sensitiser Non-Sensitiser	ClassificationRun 1Sensitiser (Extreme)921Sensitiser (Strong)500Sensitiser (Moderate)1956Sensitiser (Moderate)526Sensitiser (Weak)129Sensitiser (Weak)2506Non-Sensitiser152Non-Sensitiser88Non-Sensitiser78	Classification Run 1 Run 2 Sensitiser (Extreme) 921 281 Sensitiser (Strong) 500 500 Sensitiser (Moderate) 1956 1443 Sensitiser (Moderate) 526 296 Sensitiser (Weak) 129 271 Sensitiser (Weak) 2506 386 Non-Sensitiser 152 36 Non-Sensitiser 88 47 Non-Sensitiser 78 192	Classification Run 1 Run 2 Run 3 Sensitiser (Extreme) 921 281 N/R Sensitiser (Strong) 500 500 N/R Sensitiser (Moderate) 1956 1443 N/R Sensitiser (Moderate) 526 296 N/R Sensitiser (Weak) 129 271 N/R Sensitiser (Weak) 2506 386 N/R Non-Sensitiser 152 36 31 Non-Sensitiser 88 47 N/R Non-Sensitiser 78 192 N/R	Classification Run 1 Run 2 Run 3 Run 1 Sensitiser (Extreme) 921 281 N/R 194 Sensitiser (Strong) 500 500 N/R 245 Sensitiser (Moderate) 1956 1443 N/R 232 Sensitiser (Moderate) 526 296 N/R 122 Sensitiser (Weak) 129 271 N/R 178 Sensitiser (Weak) 2506 386 N/R 361 Non-Sensitiser 152 36 31 171 Non-Sensitiser 88 47 N/R 85 Non-Sensitiser 78 192 N/R 192	Classification Run 1 Run 2 Run 3 Run 1 Run 2 Sensitiser (Extreme) 921 281 N/R 194 256 Sensitiser (Strong) 500 500 N/R 245 177 Sensitiser (Moderate) 1956 1443 N/R 232 192 Sensitiser (Moderate) 526 296 N/R 122 338 Sensitiser (Weak) 129 271 N/R 178 156 Sensitiser (Weak) 2506 386 N/R 361 130 Non-Sensitiser 152 36 31 171 97 Non-Sensitiser 88 47 N/R 85 85 Non-Sensitiser 78 192 N/R 192 114	Classification Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 Sensitiser (Extreme) 921 281 N/R 194 256 N/R Sensitiser (Strong) 500 500 N/R 245 177 N/R Sensitiser (Moderate) 1956 1443 N/R 232 192 N/R Sensitiser (Moderate) 526 296 N/R 122 338 N/R Sensitiser (Weak) 129 271 N/R 178 156 N/R Sensitiser (Weak) 2506 386 N/R 361 130 N/R Non-Sensitiser 152 36 31 171 97 62 Non-Sensitiser 88 47 N/R 85 85 N/R Non-Sensitiser 78 192 N/R 192 114 N/R	Classification Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 Run 3 Run 3 Classification Sensitiser (Extreme) 921 281 N/R 194 256 N/R Positive Sensitiser (Strong) 500 500 N/R 245 177 N/R Positive Sensitiser (Moderate) 1956 1443 N/R 232 192 N/R Positive Sensitiser (Moderate) 526 296 N/R 122 338 N/R Positive Sensitiser (Weak) 129 271 N/R 178 156 N/R Positive Sensitiser (Weak) 2506 386 N/R 361 130 N/R Positive Non-Sensitiser 152 36 31 171 97 62 Negative Non-Sensitiser 88 47 N/R 192 114 N/R Negative	



CONCLUSIONS

Charles River Laboratories has demonstrated technical proficiency in DPRA, ARE-Nrf2 Luciferase tests, U-SENS™ and h-CLAT. Fit-for-purpose validations correctly assigning the skin sensitization potential of the chemical proficiency panels have been conducted. DPRA correctly assigned 12 sensitizers and 4 non-sensitizers. ARE-Nrf2 Luciferase (KeratinoSens™ and LuSens) tests both correctly assigned 6 sensitizers and 4 non-sensitizers. h-CLAT correctly assigned 6 weak to extreme sensitizers and 4 non-sensitizers. U-SENS™ was tested on a larger panel of 38 chemicals resulting in 98% sensitivity, 90% specificity and 94% accuracy.

In conclusion, a strategic battery of 3 tests, along with an appropriate *in silico* prediction model (e.g. Derek) combined with a weight of evidence approach, such as the 2 out of 3 model proposed by Bauch *et al.* (2012) and outlined in this poster allows for sensitive and appropriate predictions to be made. Inconclusive results may require to be clarified by LLNA, if appropriate. Potency assessment, as required, may be DEREK-based or by utilising LLNA testing.

References

Alépée *et al.* (2015) Toxicology *In Vitro* 30; 373 -382 Piroird *et al.* (2015) Toxicology *In Vitro* 29; 901-916 Bauch *et al.* (2012). Regul Toxicol Pharmacol;63(3); 489-504

Ke

A: Values from highest non-toxic dose N/R: Not Required, WoE: Weight of Evidence

UVCB Substance of Unknown or Variable composition, complex reaction products or biological materials